A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients

<table>Kaplan-Meier graph of the course of PRDFS for<i> Viscum</i> and Etoposide patients, respectively, over the period of the trial and during follow-up. The vertical line indicates the end of the trial period. Last dates are from July 2013 and are updated on an ongoing basis.</table>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients 